Resistance to Targeted Therapies in Human Cancer, 2nd Edition

Dear Colleagues,

Targeted therapies that inhibit the action of cancer-specific molecules have been widely used as standard-of-care treatments for multiple solid tumors, including lung, breast, and ovarian cancers, as well as other types of human cancers. A broad range of small molecule inhibitors or monoclonal antibodies targeting various proteins involved in cancer cell survival and growth, such as receptor tyrosine kinases and downstream signaling molecules, cyclin-dependent kinases, and nuclear receptors, have been approved or have entered clinical trials for use in cancer treatment.

Despite the benefits of targeted therapies with remarkably improved survival outcomes and reduced side effects, the high prevalence of innate and acquired resistances to the therapies, leading to tumor recurrence and metastasis after treatment, remains a major problem in the treatment of cancers, requiring a need to discover novel biomarkers and combination treatment strategies to overcome the resistance to conventional targeted therapies in human cancers.

This Special Issue will cover all aspects of cancer-targeted therapies, including mechanisms underlying the innate and acquired resistances to anti-cancer drugs targeting specific molecules, screening and identification of potential actionable therapeutic targets and their associated drugs, and new therapeutic strategies for refractory cancers with drug resistance. Original research and review articles contributing to these topics may be included in this Special Issue.

Dr. Jeong-yeon Lee
Prof. Dr. Kyung-min Lee
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cancer
• targeted therapies
• drug resistance
• biomarkers
• anti-cancer drugs
• receptor tyrosine kinases
• signaling pathways
• cancer cell growth
• cancer cell survival
• anti-tumor effect